Here are the 10-K annual reports from Reviva Pharma Holdings Inc (RVPH) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RVPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVPH filings page.
Reviva Pharmaceuticals Holdings, Inc. files its annual report describing a late-stage CNS and inflammatory disease pipeline led by brilaroxazine for schizophrenia. The company reports positive results from a large Phase 3 RECOVER trial and a 12‑month extension showing durable efficacy and generally favorable safety.
FDA has asked Reviva to run an additional Phase 3 schizophrenia study (RECOVER‑2) using 30 mg and 50 mg doses before submitting a new drug application, with trial activities expected to start in 2026 and completion targeted for 2027. Brilaroxazine also holds orphan drug designations for pulmonary arterial hypertension and idiopathic pulmonary fibrosis and has encouraging preclinical data in both.
To support operations and development, Reviva executed a May 2025 at‑the‑market program and a March 2026 public offering, raising cash through common stock, pre‑funded warrants and common warrants. A 1‑for‑20 reverse stock split became effective in March 2026, and shares outstanding were 12,810,377 as of March 27, 2026.